Detailed Information
Cited 0 time in 
Cited 3 time in 
Cited 3 time in
Metadata Downloads
Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year updateopen access
- Authors
- Dispenzieri, A.[Dispenzieri, A.]; Coelho, T.[Coelho, T.]; Conceição, I.[Conceição, I.]; Waddington-Cruz, M.[Waddington-Cruz, M.]; Wixner, J.[Wixner, J.]; Kristen, A.V.[Kristen, A.V.]; Rapezzi, C.[Rapezzi, C.]; Planté-Bordeneuve, V.[Planté-Bordeneuve, V.]; Gonzalez-Moreno, J.[Gonzalez-Moreno, J.]; Maurer, M.S.[Maurer, M.S.]; Grogan, M.[Grogan, M.]; Chapman, D.[Chapman, D.]; Amass, L.[Amass, L.]; Pavia, P.G.[Pavia, P.G.]; Tarnev, I.[Tarnev, I.]; Costello, J.G.[Costello, J.G.]; Briseno, M.A.G.D.[Briseno, M.A.G.D.]; Schmidt, H.[Schmidt, H.]; Drachman, B.[Drachman, B.]; Barroso, F.A.[Barroso, F.A.]; Yamashita, T.[Yamashita, T.]; Lairez, O.[Lairez, O.]; Sekijima, Y.[Sekijima, Y.]; Vita, G.[Vita, G.]; Jeon, E.-S.[Jeon, E.-S.]; Hanna, M.[Hanna, M.]; Slosky, D.[Slosky, D.]; Luigetti, M.[Luigetti, M.]; LoRusso, S.[LoRusso, S.]; Beamud, F.M.[Beamud, F.M.]; Adams, D.[Adams, D.]; Moelgaard, H.[Moelgaard, H.]; Press, R.[Press, R.]; Cirami, C.L.[Cirami, C.L.]; Nienhuis, H.[Nienhuis, H.]; Plana, J.M.C.[Plana, J.M.C.]; Inamo, J.[Inamo, J.]; Jacoby, D.[Jacoby, D.]; Emdin, M.[Emdin, M.]; Quan, D.[Quan, D.]; Hummel, S.[Hummel, S.]; Witteles, R.[Witteles, R.]; Dori, A.[Dori, A.]; Shah, S.[Shah, S.]; Lenihan, D.[Lenihan, D.]; Azevedo, O.[Azevedo, O.]; Murali, S.[Murali, S.]; Zivkovic, S.[Zivkovic, S.]; Low, S.C.[Low, S.C.]; Nativi-Nicolau, J.[Nativi-Nicolau, J.]; Fine, N.[Fine, N.]; Tallaj, J.[Tallaj, J.]; Tschoepe, C.[Tschoepe, C.]; Torrón, R.F.[Torrón, R.F.]; Polydefkis, M.[Polydefkis, M.]; Merlini, G.[Merlini, G.]; Badelita, S.[Badelita, S.]; Gottlieb, S.[Gottlieb, S.]; Tauras, J.[Tauras, J.]; Correia, E.B.[Correia, E.B.]; Ventura, H.[Ventura, H.]; Gess, B.[Gess, B.]; Darstein, F.[Darstein, F.]; Oh, J.[Oh, J.]; Marburger, T.[Marburger, T.]; Van, Cleemput J.[Van, Cleemput J.]; Salutto, V.L.[Salutto, V.L.]; Parman, Y.[Parman, Y.]; Chao, C.-C.[Chao, C.-C.]; Sarswat, N.[Sarswat, N.]; Mueller, C.[Mueller, C.]; Steidley, D.[Steidley, D.]; Ralph, J.[Ralph, J.]; Warner, A.[Warner, A.]; Cotts, W.[Cotts, W.]; Hoffman, J.[Hoffman, J.]; Rugiero, M.[Rugiero, M.]; Misawa, S.[Misawa, S.]; Blanco, J.L.M.[Blanco, J.L.M.]; Davila, L.G.[Davila, L.G.]; Sadeh, M.[Sadeh, M.]; Luo, J.[Luo, J.]; Kyriakides, T.[Kyriakides, T.]; Wang, A.[Wang, A.]; Kaufmann, H.[Kaufmann, H.]; Zivkovic, S.[Zivkovic, S.]; the THAOS investigators[the THAOS investigators]
- Issue Date
- Dec-2022
- Publisher
- BioMed Central Ltd
- Keywords
- Amyloidosis; Cardiomyopathy; Polyneuropathy; Registry; Transthyretin
- Citation
- Orphanet Journal of Rare Diseases, v.17, no.1
- Indexed
- SCIE
SCOPUS
- Journal Title
- Orphanet Journal of Rare Diseases
- Volume
- 17
- Number
- 1
- ISSN
- 1750-1172
- Abstract
- Background: Transthyretin amyloidosis (ATTR amyloidosis) is a rare, life-threatening disease caused by the accumulation of variant or wild-type (ATTRwt amyloidosis) transthyretin amyloid fibrils in the heart, peripheral nerves, and other tissues and organs. Methods: Established in 2007, the Transthyretin Amyloidosis Outcomes Survey (THAOS) is the largest ongoing, global, longitudinal observational study of patients with ATTR amyloidosis, including both inherited and wild-type disease, and asymptomatic carriers of pathogenic TTR mutations. This descriptive analysis examines baseline characteristics of symptomatic patients and asymptomatic gene carriers enrolled in THAOS since its inception in 2007 (data cutoff: August 1, 2021). Results: This analysis included 3779 symptomatic patients and 1830 asymptomatic gene carriers. Symptomatic patients were predominantly male (71.4%) and had a mean (standard deviation [SD]) age of symptom onset of 56.3 (17.8) years. Val30Met was the most common genotype in symptomatic patients in South America (80.9%), Europe (55.4%), and Asia (50.5%), and more patients had early- versus late-onset disease in these regions. The majority of symptomatic patients in North America (58.8%) had ATTRwt amyloidosis. The overall distribution of phenotypes in symptomatic patients was predominantly cardiac (40.7%), predominantly neurologic (40.1%), mixed (16.6%), and no phenotype (2.5%). In asymptomatic gene carriers, mean (SD) age at enrollment was 42.4 (15.7) years, 42.4% were male, and 73.2% carried the Val30Met mutation. Conclusions: This 14-year global overview of THAOS in over 5000 patients represents the largest analysis of ATTR amyloidosis to date and highlights the genotypic and phenotypic heterogeneity of the disease. ClinicalTrials.gov Identifier: NCT00628745. © 2022, The Author(s).
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.